| HOME >> BIOLOGY >> TECHNOLOGY |
• Biotechnology offers a means to address unmet medical needs, particularly via personalized medicine, which small molecule approaches do not. With more than 3,500 biotech drug companies around the world, many have developed unique technologies and approaches to drug development.
• Because drug makers must continue to introduce new products, maintaining high productivity is key. Biotech tech transfer offers a means to achieve this by providing technology sponsors with access to new technologies.
Key findings from this report
• After a decline in 2008 to 53 deals from 74 deals in 2007, biotech technology transfer volume for human medicines spiked in 2009 to 121 deals. Chapter 1
• More than half of biotech tech transfer deals fail. Chapter 2
• However, some firms experience very low failure rates of less than 10% while others report very high failure rates in excess of 70%. Chapter 2
• Many biotech tech transfer failures can be traced to an inability on the part of the sponsor to adequately perform initial due diligence. Chapter 3
• Over the next five years, the role of biotechnology in drug development is expected to expand strongly as biotech drug sales rise by 17.7% per year while small molecule drug sales grow by just 2.9% annually. Chapter 4
Key questions answered
• Why is biotech tech transfer rising so quickly? (Because biotechnologies offer a means to address unmet medical needs and many new technologies have been developed outside of Big Pharma)
• Which types of biotech tech transfer approaches are currently most common? (Licensing and acquisitions)
• Which trends will further boost biotech tech transfer in the future? (Economic recovery, healthcare reform, clarification of biosimilars regulation, rising biotech fund
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |